umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting
Umeå University, Faculty of Medicine, Department of Community Medicine and Rehabilitation, Geriatric Medicine.
Show others and affiliations
2007 (English)In: Dementia and Geriatric Cognitive Disorders, ISSN 1420-8008, E-ISSN 1421-9824, Vol. 23, no 3, 150-160 p.Article in journal (Refereed) Published
Resource type
Text
Abstract [en]

Background/Aims: Clinical short- term trails have shownpositive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated.

Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years.

Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% Cl, 3.0-4.7) and the ADAS-cog rise was 8.2 points ( 95% Cl, 6.4-10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5-16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment.

Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting.

Place, publisher, year, edition, pages
Basel: S. Karger, 2007. Vol. 23, no 3, 150-160 p.
Keyword [en]
Alzheimer's disease, cholinesterase inhibitor, donepezil
National Category
Geriatrics Neurology Psychiatry
Identifiers
URN: urn:nbn:se:umu:diva-118228DOI: 10.1159/000098052ISI: 000244108300003PubMedID: 17312368OAI: oai:DiVA.org:umu-118228DiVA: diva2:916693
Available from: 2016-04-04 Created: 2016-03-14 Last updated: 2016-04-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Eriksson, StureNäsman, BirgittaEkdahl, Anne
By organisation
Geriatric Medicine
In the same journal
Dementia and Geriatric Cognitive Disorders
GeriatricsNeurologyPsychiatry

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 21 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf